pharma · Dermatomyositis · Diffuse Cutaneous Systemic Sclerosis · CRBP
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings
Corbus Pharmaceuticals clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 500 River Ridge Dr, Norwood, Massachusetts 02062, US
- Founded
- 2014
- Employees
- 57
- Programs
- 11
- Drugs
- 3
- Patents
- 6
Corbus Pharmaceuticals projects
8 ClinicalTrials.gov programs sponsored by Corbus Pharmaceuticals.
Corbus Pharmaceuticals has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
A Clinical Trial for Patients with Advanced Cancers
Corbus Pharmaceuticals Holdings
Advanced Solid tumour
1 trial -
CRB-601 monoclonal antibody
Corbus Pharmaceuticals Holdings
Solid Tumor
1 trial -
CRB-701
Corbus Pharmaceuticals Holdings
Solid Tumor, Adult
1 trial -
JBT-101
Corbus Pharmaceuticals Holdings
Diffuse Cutaneous Systemic Sclerosis
1 trial -
JBT-101
Corbus Pharmaceuticals Holdings
Dermatomyositis
1 trial -
JBT-101
Corbus Pharmaceuticals Holdings
Systemic Lupus Erythematosus
1 trial -
JBT-101 (lenabasum)
Corbus Pharmaceuticals Holdings
Cystic Fibrosis
1 trial -
Lenabasum 20 mg
Corbus Pharmaceuticals Holdings
Cystic Fibrosis
1 trial
Frequently asked questions
How many clinical projects does Corbus Pharmaceuticals have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.